IQVIA Holdings Inc (IQV) -- Resilient Growth in Drug Development | Artisan Select Equity Q3 2026

gurufocus.com · 2026-10-23

Shares increased 39% as demand trends in drug development improved.Strong positioning in the contract research organization (CRO) space.Risks include potential

TickrTrends take: IQVIA operates in the Healthcare sector where demand for drug development services remains steady, supporting its current Fairly valued assessment by TickrTrends. As the company demonstrates resilient growth in its core drug development business, investors tracking valuation should monitor whether this operational performance can sustain current price levels or potentially narrow any valuation gaps that may emerge. The consistency of growth in this segment will be particularly important for determining if the Fairly valued designation holds as market conditions evolve.

Read the full story at gurufocus.com →